Symbol="IMTX"
AssetType="Common Stock"
Name="Immatics NV"
Description="Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in the United States. The company is headquartered in Tbingen, Germany."
CIK="1809196"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="PAUL EHRLICH-STRASSE 15, TUBINGEN, DE"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="867155000"
EBITDA="-61604000"
PERatio="None"
PEGRatio="None"
BookValue="2.61"
DividendPerShare="0"
DividendYield="0"
EPS="-1.17"
RevenuePerShareTTM="1.128"
ProfitMargin="-0.852"
OperatingMarginTTM="-0.815"
ReturnOnAssetsTTM="-0.123"
ReturnOnEquityTTM="-0.43"
RevenueTTM="79720000"
GrossProfitTTM="172831000"
DilutedEPSTTM="-1.17"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.905"
AnalystTargetPrice="18.23"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4.703"
PriceToBookRatio="6.18"
EVToRevenue="2.833"
EVToEBITDA="9.92"
Beta="0.5"
num_52WeekHigh="13.6"
num_52WeekLow="5.9"
num_50DayMovingAverage="10.8"
num_200DayMovingAverage="9.41"
SharesOutstanding="76672000"
DividendDate="None"
ExDividendDate="None"
symbol="IMTX"
open="11.29"
high="11.59"
low="11.18"
price="11.31"
volume="199957.00"
latest_trading_day="2023-07-17"
previous_close="11.25"
change="0.06"
change_percent="0.5333%"
aroon_positive_momentum_days="52"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="52"
Volume_recent_avg="408388"
Change_recent_avg="-0.01"
Delta_recent_avg="0.52"
Variance_recent_avg="0.26"
Change_ratio_recent_avg="-0.26"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="52"
Aroon_momentum_negative="48"
image_negative_thumbnail_id_1="500"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0105.jpeg"
image_negative_thumbnail_id_2="518"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0087.jpeg"
image_neutral_thumbnail_id_1="521"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0078.jpeg"
image_neutral_thumbnail_id_2="573"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0026.jpeg"
image_positive_thumbnail_id_1="603"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0105.jpeg"
image_positive_thumbnail_id_2="703"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0005.jpeg"
image_professor_thumbnail_id_1="1176"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0010.jpeg"
image_professor_thumbnail_id_2="1192"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0026.jpeg"
